Gamma oryzanol is a rice bran dietary supplement and Japanese oral medication for cholesterol, blood sugar, menopausal comfort, mood, and strength. Every human benefit carries Low evidence; antioxidant, liver, and anticancer effects are Speculative. Fortified oils and hormone combinations drive metabolic and menopausal gains, while oral capsules rarely beat placebo outside untrained strength. Adverse events match placebo, though thyroid-stimulating hormone suppression requires paired free thyroid hormone testing. (Full Review)
| Marker | Target | Why |
|---|---|---|
| LDL-C | No established target; tracks ≥8%–12% reduction from individual baseline | Efficacy marker: primary atherogenic lipid fraction expected to decrease with gamma-oryzanol or enriched rice bran oil. |
| Fasting Glucose & HbA1c | Fasting glucose 70–99 mg/dL; HbA1c 4.0%–5.6% (standard reference range) | Efficacy marker: evaluates glycemic response to gamma-oryzanol interventions in insulin-resistant or diabetic adults. |
| hs-CRP | No established target; tracks reduction from individual baseline | Efficacy marker: tracks reductions in low-grade systemic inflammation observed with gamma-oryzanol-fortified oil. |
| TSH & Free T4 | TSH 0.4–4.5 mIU/L; Free T4 0.8–1.8 ng/dL (standard reference range) | Safety check: detects hypothalamic-pituitary TSH suppression at doses ≥300 mg/day that alters thyroid management. |
| ALT & AST | ALT 7–56 U/L; AST 8–33 U/L (standard reference range) | Safety check: screens for rare idiosyncratic hepatic transaminase elevations noted in pharmaceutical labeling. |
Cadence: Baseline prior to initiation; recheck TSH and free T4 at 4–6 weeks (when taking ≥300 mg/day or thyroid hormone replacement); reassess lipid, glycemic, inflammatory, and hepatic markers at 8–12 weeks; repeat every 6 months during maintenance.